Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery by Bhattarai, Narayan et al.
181
o r i g i n a l   r e s e a r c h
international Journal of nanomedicine 2006:1(2) 181–187
© 2006 Dove Medical Press limited. all rights reserved
Abstract: Nanoparticles of ~10 nm in diameter made with chitosan or lactic acid-grafted 
chitosan were developed for high drug loading and prolonged drug release. A drug encapsulation 
efficiency of 92% and a release rate of 28% from chitosan nanoparticles over a 4-week period 
were demonstrated with bovine serum protein. To further increase drug encapsulation, prolong 
drug release, and increase chitosan solubility in solution of neutral pH, chitosan was modified 
with lactic acid by grafting D,L-lactic acid onto amino groups in chitosan without using a catalyst. 
The lactic acid-grafted chitosan nanoparticles demonstrated a drug encapsulation efficiency of 
96% and a protein release rate of 15% over 4 weeks. With increased protein concentration, the 
drug encapsulation efficiency decreased and drug release rate increased. Unlike chitosan, which 
is generally soluble only in acid solution, the chitosan modified with lactic acid can be prepared 
from solutions of neutral pH, offering an additional advantage of allowing proteins or drugs to 
be uniformly incorporated in the matrix structure with minimal or no denaturization.
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Introduction
A number of polymeric nanoparticles have been synthesized and studied in the past 
few years as promising drug delivery systems to improve delivery efficiency and 
reduce side-effects of drug toxicity (Uhrich et al 1999; Ranney 2000; Soppimath et al 
2001). Nanoscale drug systems can circumvent the rapid recognition by the immune 
system and deliver drugs to cells with high efficiency compared with microparticle-
based system (LaVan et al 2003). Among those investigated, chitosan-based materials 
have drawn considerable attention in view of chitosan’s excellent biocompatibility, 
biodegradability, and reactive surface functional groups for easy surface modification 
(Dodane and Vilivadam 1998; Paul and Sharma. 2000; Janes et al 2001; Drury and 
Mooney 2003). The positively charged amino groups of chitosan tend to adhere to the 
negatively charged cell surfaces, facilitating the penetration of chitosan nanoparticles 
across the cell membrane (Artursson et al 1994; Borchard et al 1996; Janes et al 
2001). 
Chitosan–drug nanoparticles have been prepared by a number of methods as 
reviewed by Janes et al (2001). 5-fluorouracil drug was incorporated in chitosan 
nanoparticles by chemical crosslinking with glutaraldehyde, targeted at anticancer 
drug delivery (Ohya et al 1994). Alternative methods were sought after the discovery 
of the negative effect of glutaraldehyde crosslinking on cell viability and the degraded 
integrity of the incorporated drug. Bodmeier et al (1989) and Calvo et al (1997) used 
an ionic gelation method to prepare chitosan particles with sizes ranging from micron 
to submicron. In this method, an anionic cross-linking agent, sodium tripolyphosphate 
(TPP), was introduced into an aqueous solution of chitosan in acetic acid (Calvo et al 
1997; Majeti 2000; Janes et al 2001; Kumar et al 2004; Zhang et al 2004). The major 
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advantage of this method is the ease in manipulation of 
particle size by changing pH values. Berthold et al (1996), 
Calvo et al (1997), and Janes et al (2001) synthesized chitosan 
nanoparticles using desolvating agents (eg, sodium sulfate) 
through the interaction of chitosan with sulfate. Though 
many advances have been made on the synthesis of chitosan 
nanoparticles and their use in short-term (eg, weeks) drug 
delivery (Calvo et al 1997; Janes and Alonso 2003; Xu and 
Du 2003; Zhang et al 2004), long-term (eg, months) drug 
release by nanoparticles remains a major challenge.
In the present study, chitosan-based nanoparticles with 
a high degree of size uniformity were prepared by grafting 
D,L-lactic acid on chitosan to serve as a drug carrier for 
prolonged drug release. The lactic acid-grafted chitosan 
(LA-g-chitosan) was prepared by dehydrating the solvent 
cast thin film of chitosan containing lactic acids. The LA-g-
chitosan nanoparticles were fabricated via a co-precipitation 
process by LA-g-chitosan in ammonium hydroxide to 
form coacervate drops. The structure of nanoparticles was 
investigated by transmission electron microscopy (TEM). 
The chemical structure and bonding were studied by nuclear 
magnetic resonance (NMR) and Fourier transformed infrared 
(FTIR) spectroscopy. Bovine serum albumin (BSA) was 
used as a model protein to examine the drug absorption and 
release characteristics of both chitosan and LA-g-chitosan 
nanoparticles in phosphate buffer saline (PBS) at pH 7.4. 
Experimental procedure
Materials
Chitosan from crab shells with 88% of deacetylation (weight 
average molar mass MW 190 kDa and Brookfield viscosity 
200–800 cps in 1% solution with 1% acetic acid), BSA 
(MW 68 kDa), and D,L-lactic acid (90% aqueous solution) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). 
Coomassie Blue G 250 was purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). 
Preparation of la-g-chitosan 
copolymer
To prepare LA-g-chitosan copolymer, chitosan powder was 
first mixed with an aqueous solution of lactic acid, and the 
mixture was stirred overnight using a magnet stirrer to create 
a final solution at a chitosan concentration of 2 wt.%. The 
solution was placed in polystyrene petri dishes and maintained 
at 70°C for 5 hours for film formation. The as-produced film 
(~0.08 mm in thickness) was heated at 80–90°C under high 
vacuum for 5 hours, and the grafted copolymer was formed 
as a result of the dehydration of the chitosan lactate salts 
and the formation of the corresponding amide linkages. The 
unreacted lactic acid and oligo(lactic acid) (OLLA) were 
removed from the grafted chitosan polymer using a Soxhlet 
apparatus by washing with chloroform and methanol solvents 
for 48 hours each.
characterization of la-g-chitosan 
copolymer
NMR spectroscopy and polarized Fourier transformed 
infrared (FTIR) spectroscopy were used to characterize 
the chemical structure and bonding characteristics of LA-
g-chitosan copolymer, respectively. For NMR, samples of 
10–20 mg each were prepared by dissolving LA-g-chitosan in 
0.7 mL of D2O containing 0.5 M DCl/D2O. 
1H-NMR spectra 
were acquired with a Bruker AV-301 spectrometer.
For FTIR spectroscopy, a dried 5-mg sample was mixed 
with 300 mg dry KBr and pressed into a pellet using a macro 
KBr die kit. The solid pellet was placed in a magnetic holder 
and the system was purged with air before testing. FTIR 
spectra of 200 scans at 4 cm
–1 resolution were acquired using 
a Nicolet 5DX spectrometer equipped with a deuterated 
triglycine sulfate (DTGS) detector and a solid transmission 
sample compartment. Spectrum analysis and display were 
performed using standard Nicolet and Microcal Origin 
software.
The ninhydrin assay was used to determine the percentile 
decrease of free amino groups in LA-g-chitosan versus pure 
chitosan, which was defined as the percentage of free amino 
groups in chitosan that had reacted with lactic acid. Both 
0.1 mg/mL solutions of chitosan and LA-g-chitosan were 
prepared in a mixture of CH3COOH (3% w/v) and HCl (1% 
w/v) under constant stirring at 20°C for 24 hours. Acetate 
buffer (0.5 mL, 4 M, pH 5.5) was then added to the resulting 
polymer solutions (0.1–0.5 mL, corresponding to 10–50 µg 
of chitosan or LA-g-chitosan). All the sample solutions 
were prepared in 5-mL glass tubes capped with a rubber 
septum. Ninhydrin reagent (2 mL, Sigma) was added to the 
sample solutions prepared above, and the tubes containing 
solution mixtures were maintained in a boiling water bath 
for 30 minutes. The solutions were then cooled down to 
room temperature, and UV absorbance of the solutions 
was acquired at 570 nm. A standard absorbance curve was 
generated using D-glucosamine (Sigma) solutions (100% 
free amino groups).international Journal of nanomedicine 2006:1(2) 183
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Preparation of chitosan and  
la-g-chitosan nanoparticles
Chitosan nanoparticles were prepared by dissolving chitosan 
powder in 0.2 M acetic acid to produce a 2 wt.% solution, 
followed by addition of the solution in ammonium hydroxide 
solution at pH 8.5–9.0. A constant solution flow rate of 
0.1 mL/min was maintained using a mini-pump. As the acetic 
chitosan solution was introduced into the basic solution, the 
opalescent suspension was formed under vigorous magnetic 
stirring at room temperature. The particles were separated 
from the solution by centrifugation. After separation, the 
particles were washed with deionized water until a pH of 
7.4 was reached. LA-g-chitosan nanoparticles were prepared 
by dissolving LA-g-chitosan film in 0.2 M acetic solution 
and then following the same procedure as for chitosan 
nanoparticles.
Bsa absorption on nanoparticles
BSA absorption on nanoparticles was carried out in PBS at 
pH 7.4 at room temperature. 200 mg of nanoparticles were 
dispersed in 6 mL of PBS solution under sonication, and BSA 
was added at varying concentrations of 0, 1.0, 2.0, 3.0, 4.0, 
or 5.0 mg/mL. The nanoparticle suspension was then left 
for 24 hours in a rotating agitator. After protein adsorption, 
the nanoparticles were separated by centrifugation, and the 
amount of free protein in the supernatant was measured. The 
supernatant in 96-well plates was analyzed using a modified 
Coomassie blue protein assay and by UV spectroscopy at 
590 nm. A calibration curve was generated at each time 
interval using nanoparticles without BSA loaded to correct for 
the intrinsic absorbance of chitosan. The BSA encapsulation 
efficiency (AE) of the process was calculated as follows:
T AE = (T – F)
 × 10
where T is the total amount of BSA added in PBS and F is the 
amount of free BSA left in supernatant after the nanoparticles 
were removed from the solution. For each BSA concentration, 
the samples were examined in triplicate, and results were 
presented as mean value ± standard deviation.
Morphology and structure 
characterization of nanoparticles
The morphology and size distribution of nanoparticles were 
examined by TEM (CM 100 TEM) at an accelerating voltage 
of 40 kV . Samples were prepared by depositing a drop of 
chitosan nanoparticle suspension on a copper grid fitted with 
a carbon support film and dried under vacuum.  
in vitro release of Bsa from 
nanoparticles
BSA loaded nanoparticles were placed in a test tube 
containing 6 mL of PBS at pH 7.4 and incubated at 37°C 
for 24 hours. At specified time intervals, 1 mL out of 6 mL 
solution was removed to a siliconized 1.5-mL microcentrifuge 
tube, and the medium in the test tube was replenished with 
1 mL of fresh PBS. The amount of BSA released from the 
nanoparticles was evaluated by the modified Coomassie blue 
protein assay method as noted above. All release tests were 
run in triplicate, and the results were reported as mean value 
± standard deviation.
Results and discussion
characterization of la-g-chitosan 
polymer
Two types of LA-g-chitosan copolymer films were obtained 
depending on the amount of lactic acid used. Copolymer films 
obtained with a lactic acid/chitosan mole ratio lower than 1.5 
(Table 1) were transparent and readily soluble in solutions 
with pH up to 7.5, while those with a lactic acid/chitosan 
ratio higher than 1.5 were light brown and yielded swollen 
hydrogels under the same condition. Compositions and 
other material properties of these LA-g-chitosan copolymers 
are shown in Table 1. During the dehydrating process, the 
formation of amide and polycondensation of lactic acid 
took place at the same time. The unreacted lactic acid and 
oligomeric lactic acid in the reaction mixture were washed 
out as impurities using excess chloroform and methanol. 
Table 1  la-g-chitosan copolymers with different compositions
  No.  Mole ratio
  % degree of
  Water solubility
    (acid/amine  substitution or
    group)
a  percentage of
      decrease of
      amino groups
b
 chitosan  –  13.2
c  soluble in ph <6 
  c1  1.5  35.8  soluble in ph <7.5
  c2  2.9  –  slightly soluble at ph 7.5
  c3  5.9  –  insoluble at ph 7.5 
  c4  11.6  –  insoluble at ph 7.5
aDifferent ratios of reactants were maintained by adding different amounts of lactic 
acid in a fixed amount of chitosan (0.5 g). Degree of substitution was not calculated 
for the la-g-chitosan with a higher fraction of lactic acid because these samples 
were not soluble in water.
bestimated by ninhydrin assay. 
cDegree of substitution in unmodified chitosan, ie, 13.2 corresponds to the degree 
of deacetylation.international Journal of nanomedicine 2006:1(2) 184
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Figure 1 shows FTIR spectra of chitosan and LA-g-
chitosan with two different ratios of lactic acid to chitosan. 
The peaks at 1655 and 1325 cm
−1 in the IR spectrum of 
chitosan (a) correspond to amide I and amide III, respectively. 
The peak at 1585 cm
−1 is the free amino band of chitosan. 
The two peaks at 902 and 1157 cm
−1 are the result of the 
saccharide structure of chitosan. The peak at 1377 cm
−1 is the 
characteristic band of CH3 symmetrical deformation mode. 
The LA-g-chitosan spectrum (b) has a broad band around 
1591 cm
−1, owing to the overlapping of the peaks from the free 
amino band of chitosan and the amide that couples chitosan 
and lactic acid oligomers. The peak at 1736 cm
−1 is attributed 
to carbonyl of ester or carboxylic groups on the lactic acid 
side chains. When LA-g-chitosan was prepared with a high 
content of lactic acid (c), the broad band around 1591 cm
−1 
was absent and multiple peaks appeared corresponding to 
the N-acetylated and free amino groups of chitosan. The 
increased intensity of the amide I peak (1655 cm
−1) indicated 
an increase in amidation resulting from the reaction of 
chitosan with increased amount of lactic acid. The peak of 
the amino groups shifted slightly from 1591 to 1598 cm
−1, 
while the intensity of the corresponding peak of the carbonyl 
group at 1740 cm
−1 increased. Compared with the reported 
IR spectrum of lactic acid and their oligomers (Kister et al 
1998), the well-resolved peaks at 1452 and 1315 cm
−1 were 
attributed to -CH3 and -CH groups in LA-g-chitosan. 
Figure 2 shows 
1H-NMR spectra of chitosan and LA-
g-chitosan. The characteristic peaks from LA-g-chitosan 
associated with chitosan and lactic acid segment were 
assigned as follows according to the data reported in the 
literature on pure chitosan and lactide oligomer (Rashkov et 
al 1996; Schwach et al 1997; Sashiwa et al 2003). Chemical 
shifts for chitosan: δ 4.9–5.2 (br, H-1), 3.45–3.90 (br, H-3, 
Figure 1  infrared spectra of (a) chitosan, (b) la-g-chitosan with acid/amine 
ratio=1.5 (sample c1, Table 1), and (c) la-g-chitosan with acid/amine ratio=11.6 
(sample c4, Table 1).
Figure 2  
1h-nMr (nuclear magnetic resonance) spectra of (a) chitosan and  
(b) la-g-chitosan (sample c1)
H-4, H-5, and H-6), 2.95 (0.85H, br s, H-2), 1.85 ppm (br 
s, NHAc). Chemical shifts for LA-g-chitosan: δ 5–5.15 (br, 
H-1 of GlcN), 4.90–5.00 (q, -CH of lactyl unit), 4.25 (q, 
-CH of hydroxylated lactyl unit), 3.50–4.0 (m, H-3, H-4, H-
5, and H-6), 2.90–3.10 (br s, H-2), 2.05 ppm (br s, NHAc), 
1.40–1.50 (d, -CH3 of lactyl units), 1.30–1.40 (d, -CH3 of 
hydroxylated lactyl units). NMR spectra shown in Figure 
2 were taken at 20°C. The appearance of a new H-2 proton 
signal at 3.22 ppm from LA-g-chitosan corresponding to 
N-alkylation of chitosan (Kumar et al 2004) confirms the 
bonding between chitosan and lactic acid. Since two peaks 
corresponding to lactyl units connected to the chitosan and 
the hydroxylated lactyl units are well separated, the 
1H-NMR 
spectra can be used to measure the degree of polymerization 
of LA (number of lactyl units) side chain grafted onto the 
chitosan. For example, the number of lactyl units for sample 
C1 shown in Table 1 was evaluated to be 1.52. When the 
number of methyl proton in hydroxylated lactyl unit is set 
to 3, the number of lactyl units multiplied by the repeat unit 
weight of 72 g mole
−1 yields the length of LA side chain 
110 g mole
−1.
characterization of nanoparticles
Figure 3 shows an exemplary TEM image of LA-g-chitosan 
nanoparticles at two magnifications. TEM images of pure 
chitosan nanoparticles were not presented since they 
appeared similar to the LA-g-chitosan nanoparticles. From 
TEM images, both chitosan and LA-g-chitosan nanoparticles 
were spherical and have an average diameter of ~10 nm international Journal of nanomedicine 2006:1(2) 185
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and a fairly uniform size distribution. Advantages of using 
small-size particles as a carrier system include high cellular 
uptake, good suspensibility, and easy penetration into arterial 
walls (Labhasetwar et al 1997). Furthermore, the particles 
with smaller sizes have larger surface area to volume ratios 
and thus may have a high drug-loading capacity and a slow 
drug-diffusion rate. 
Protein encapsulation and interaction 
with chitosan 
Drug AE of chitosan and LA-g-chitosan nanoparticles in   
BSA solutions of different concentrations was evaluated 
following the procedure outlined above. The AEs of both 
chitosan and LA-g-chitosan nanoparticles in BSA solution 
with an initial BSA concentration of 1 mg/mL were measured 
to be 92% and 96%, respectively. The high AEs of chitosan 
and LA-g-chitosan may be attributed to the small size of 
particles that have a high surface to volume ratio and high 
electrostatic interaction between the negatively charged 
moieties on BSA and the positively charged amine groups 
on chitosan. The fact that LA-g-chitosan nanoparticles had 
a higher AE than chitosan nanoparticles may be attributed 
to additional hydrophobic interactions of the LA-g-chitosan 
particles with BSA. In the present work, no linker molecules 
were used to bind BSA with the polymer and thus only the 
adsorption owing to the electrostatic attractions between 
BSA proteins and nanoparticles and the direct entrapment 
of protein into the polymer matrix would contribute to 
the drug loading. This helps retain protein integrity and 
biofunctionality. Our preliminary results on polyacrylamide 
gel electrophoresis showed that the integrity of the BSA 
released from the nanoparticles was retained throughout the 
release period (data not shown). 
Protein release study
Figure 4 shows the percent cumulative release rate of BSA 
from chitosan and LA-g-chitosan nanoparticles loaded with 
BSA at different concentrations, over a 4-week period. 
For both types of nanoparticles, the protein release rates 
increased with increased BSA loading concentrations. The 
release of BSA from nanoparticles is mainly driven by the 
protein concentration gradient. The encapsulation of high 
Figure 3  Transmission electron micrograph of la-g-chitosan nanoparticles.
Figure 4  Bovine serum albumin (Bsa) release profiles of (a) chitosan and (b) la-g-chitosan nanoparticles at different Bsa loading concentrations. Data shown are the 
mean ± standard deviation (n=3). 
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concentration produced a greater concentration gradient 
between the polymer and release medium leading to a higher 
diffusion rate (Miyazaki et al 1988; Janes et al 2001; Xu 
and Du 2003). Consequently, these results show that it is 
possible to modulate the protein release rate by adjusting 
the initial protein concentration. All the drug-release profiles 
exhibit an initial burst release, presumably from the particle 
surface, followed by a sustained release driven by diffusion 
of the protein through the polymer wall and polymer 
erosion. The release profiles of chitosan and LA-g-chitosan 
particles are similar, but the BSA release rate from chitosan 
nanoparticles is significantly higher than from LA-g-chitosan 
nanoparticles. For example, the burst releases from chitosan 
and LA-g-chitosan loaded with BSA at a concentration 
of 1 mg/mL were about 15% and 10%, respectively. The 
BSA releases from chitosan and LA-g-chitosan over a 4-
week period at BSA concentration of 1 mg/mL were 28% 
and 15%, respectively. The sustained BSA releases from 
both chitosan and LA-g-chitosan nanoparticles might be 
attributed to strong intermolecular interactions, including 
hydrogen bonding and dipole–dipole interactions between 
chitosan and BSA molecules. Previous studies (Miyazaki et 
al 1988; Janes et al 2001; Xu and Du 2003) suggested that 
the mechanism of association of proteins with chitosan is, 
at least, partially mediated by the ionic interaction between 
chitosan and protein macromolecules. It is known that lactic 
acid oligomers are hydrophobic, and introduction of this 
hydrophobic moiety to chitosan could substantially alter the 
physicochemical properties of the chitosan nanoparticles 
for BSA absorption. Thus, the slower drug release from LA-
g-chitosan than chitosan might be attributed to additional 
intermolecular forces, including hydrophobic interactions 
and hydrogen bonding. More in-depth research is needed to 
reveal and confirm the underlying mechanism and their roles 
in association of BSA with LA-g-chitosan.
Summary 
Spherical and uniformly dispersed chitosan and lactic 
acid-modified chitosan (LA-g-chitosan) nanoparticles 
with a mean diameter of ~10 nm were prepared. Albumin 
encapsulation efficiency as high as 92% and 96% was attained 
for chitosan and LA-g-chitosan nanoparticles, respectively. 
The BSA release profiles of both chitosan and LA-g-chitosan 
nanoparticles exhibit an initial burst release, followed by a 
sustained quasi-linear release. The chitosan nanoparticles 
have a protein release rate of 28% over a 4-week period and 
predicated complete protein release up to 3 months, while 
LA-g-chitosan nanoparticles had a protein release rate of 15% 
at the same protein concentration over a 4-week period and 
predicated complete release up to 6 months. By incorporating 
the lactyl segment into the chitosan backbone, the resulting 
nanoparticle reduces the burst release, but the release pattern 
was similar to that of the pure chitosan nanoparticles. Since 
most proteins and cell membranes are negatively charged, 
these nanoparticles are also expected to be potential vehicles 
to associate more easily with other proteins and subsequently 
internalized by the target cells than negatively charged 
nanoparticles.
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